Atlas Molecular Pharma Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3.51M
- Investors
-
13
Atlas Molecular Pharma General Information
Description
Developer of therapeutic drugs designed to treat rare diseases. The company specializes in the identification of molecules or drugs that provide stability to proteins whose dysfunction is responsible for the development of rare diseases, enabling medical practitioners to improve the quality of their patients' lives cost-effectively.
Contact Information
Website
www.atlasmolecularpharma.comCorporate Office
- Parque Científico y Tecnológico de Bizkaia
- Edificio 801-A
- 48160 Derio
- Spain
Corporate Office
- Parque Científico y Tecnológico de Bizkaia
- Edificio 801-A
- 48160 Derio
- Spain
Atlas Molecular Pharma Timeline
Atlas Molecular Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 16-Jan-2026 | $3.51M | Completed | Clinical Trials - Phase 1 | ||
| 10. Grant | 01-Jan-2025 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC | 26-Oct-2023 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC | 14-Oct-2022 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 13-Apr-2021 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 29-Jan-2020 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 16-Mar-2018 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 14-Mar-2017 | Completed | Startup | |||
| 3. Early Stage VC | 01-Feb-2017 | $213K | $387K | Completed | Startup | |
| 2. Early Stage VC | 21-Dec-2016 | $174K | $174K | Completed | Startup |
Atlas Molecular Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 6,710 | $1.056307 | $145.77 | $145.77 | 1x | $145.77 | 26.12% | |
| Ordinary | 1,644 | $1.056307 | $105.63 | $105.63 | 1x | $105.63 | 6.4% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Atlas Molecular Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Atlas Molecular Pharma Patents
Atlas Molecular Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4389123-A1 | Uroporphyrin as therapeutic compound against prion diseases | Inactive | 20-Dec-2022 | ||
| JP-2026502145-A | Uroporphyrin i as a therapeutic compound for prion diseases | Pending | 20-Dec-2022 | ||
| EP-4637759-A1 | Uroporphyrin i as therapeutic compound against prion diseases | Active | 20-Dec-2022 | ||
| WO-2024133215-A1 | Uroporphyrin i as therapeutic compound against prion diseases | Inactive | 20-Dec-2022 | ||
| EP-4637759-B1 | Uroporphyrin i for use in the treatment of prion diseases | Active | 20-Dec-2022 | A61K31/409 |
Atlas Molecular Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Atlas Molecular Pharma Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CDTI Innvierte | Government | Minority | ||
| Center for Industrial Technological Development | Corporation | Minority | ||
| FDA Orphan | Other | |||
| Endometrial DIDI | Venture Capital | Minority | ||
| Ezten Venture Capital Fund | Venture Capital | Minority |
Atlas Molecular Pharma FAQs
-
When was Atlas Molecular Pharma founded?
Atlas Molecular Pharma was founded in 2015.
-
Where is Atlas Molecular Pharma headquartered?
Atlas Molecular Pharma is headquartered in Derio, Spain.
-
What is the size of Atlas Molecular Pharma?
Atlas Molecular Pharma has 8 total employees.
-
What industry is Atlas Molecular Pharma in?
Atlas Molecular Pharma’s primary industry is Drug Discovery.
-
Is Atlas Molecular Pharma a private or public company?
Atlas Molecular Pharma is a Private company.
-
What is Atlas Molecular Pharma’s current revenue?
The current revenue for Atlas Molecular Pharma is .
-
How much funding has Atlas Molecular Pharma raised over time?
Atlas Molecular Pharma has raised $8.08M.
-
Who are Atlas Molecular Pharma’s investors?
CDTI Innvierte, Center for Industrial Technological Development, FDA Orphan, Endometrial DIDI, and Ezten Venture Capital Fund are 5 of 13 investors who have invested in Atlas Molecular Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
